Idiopathic pulmonary fibrosis (IPF) is a progressive disease that causes respiratory failure. However, treatment for IPF is limited because there are no effective therapeutic agents to date. Since it has been known that bleomycin, an anticancer drug, causes pulmonary fibrosis, IPF model animals have been produced by administration of bleomycin in the lung. In the present study, we attempted to create the IPF model by oropharyngeal aspiration (OPA) of bleomycin and the effects of Nintedanib were evaluated. C57BL/6N male mice were administered bleomycin via OPA at day 0. Nintedanib at 10 or 30 mg/kg were orally administered twice a day from days 0 to 21. We evaluated the effects of Nintedanib by means of Micro-CT lung imaging, quantification of cytokine levels in bronchoalveolar lavage fluid (BALF), hydroxyproline (HYP) level in the lung, pulmonary function test, and pathological examinations in the lung. As results, the control group showed higher levels of HYP, as well as TGF-β1, IL-12 (p40) and eotaxin in BALF than those in the normal group, showing induction of fibrosis. The Nintedanib 30 mg/kg group showed lower levels of HYP, TGF-β1 and IL-12 (p40) than those in the control group. These results indicated that Nintedanib has anti-fibriotic effects on IPF.